Frankfurt - Delayed Quote • EUR GlycoMimetics, Inc. (GKO.F) Follow 1.5780 -0.1280 (-7.50%) At close: April 26 at 8:02 AM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for GKO.F 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: GKO.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript Q4 2023 GlycoMimetics Inc Earnings Call GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 Positive Signs As Multiple Insiders Buy GlycoMimetics Stock GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
